静脉固态肿瘤临床试验中目标存活时间动态预测

Dynamic Prediction of the Target Survival Time in Metastatic Solid Tumor Cancer Clinical Trials

Overall survival (OS) is the gold standard for assessing patient benefit and cost-effectiveness of new cancer drugs. However, it is often difficult to use OS as the primary endpoint in randomized clinical trials (RCTs) for patients with metastatic cancer due to multiple reasons. In recent years, progression-free survival (PFS) has increasingly been used as the primary endpoint in metastatic cancer RCTs to accelerate development. However, regulatory authorities often seek mature OS data for approval. Therefore, it is critical to determine the target time when OS data are expected to be mature for reliable statistical inference. Motivated by an advanced renal cell carcinoma (RCC) clinical trial, we develop and investigate different prediction models leveraging information from disease progression to improve target OS prediction times. We propose a multivariate joint modeling approach considering components of progression and OS and extend three models commonly used for association to be used for OS prediction. To the best of our knowledge, this is the first comprehensive statistical study exploring the prediction of OS using different levels of information on disease progression and illustrating these models using a real, complex dataset. Our findings have significant implications for OS prediction.